Neosoma's technology was utilized in a clinical study led by Benjamin Ellingson, PhD, to investigate early volumetric, perfusion, and diffusion MRI changes in IDH1-mutant gliomas during IDH inhibitor treatment.
The authors summarized the importance of the study as follows:
There remains no standard of care for isocitrate dehydrogenase (IDH)-mutant gliomas. IDH inhibitors are novel, targeted therapies that have only recently been explored for human IDH-mutant gliomas, so imaging biomarkers of treatment efficacy are largely unexplored. We report that early changes in perfusion, apparent diffusion coefficient, and fluid-attenuated inversion recovery hyperintensity volume after 2–4 months of treatment are significantly associated with progression-free survival benefit following IDH inhibitor treatment response in IDH1-mutant gliomas. Together, data suggest a combination of early tumor size, vascularity, and diffusion changes may be useful for clinical interpretation of treatment response and tumor progression in IDH1-mutant gliomas treated with IDH inhibitors.
To read the full paper in Neuro-Oncology Advances, please follow this link.